

## Prognostic and clinicopathological significance of long noncoding RNA H19 overexpression in human solid tumors: evidence from a meta-analysis


## SUPPLEMENTARY FIGURES AND TABLES



Supplementary Figure S1: Meta-analysis for the pooled HRs of OS stratified by the cancer type.




Supplementary Figure S2: Meta-analysis for the pooled HRs of OS stratified by the analysis type.




Supplementary Figure S3: Meta-analysis for the pooled HRs of OS stratified by the sample size.


## (2) Association between lncRNA-H19 expression and clinicopathological parameters:



Supplementary Figure S4: The correlation between H19 expression and gender (male vs. female).




Supplementary Figure S5: The correlation between H19 expression and tumor differentiation (poorly/others vs. well/moderately).



Supplementary Figure S6: The correlation between H19 expression and lymph node metastasis (+ vs.-).

	High expression		Low expression		Odds Ratio			Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
Wang,2015	9	42	2	50	23.6%	6.55 [1.33, 32.26]	2015	
Huang,2015	10	66	30	67	30.0%	0.22 [0.10, 0.50]	2015	
Han,2016	20	48	23	35	29.5%	0.37 [0.15, 0.92]	2016	
Chen,2016	2	64	1	64	17.0%	2.03 [0.18, 22.99]	2016	
Total (95% CI)		220		216	100.0%	0.83 [0.20, 3.46]		•
Total events	41		56					
Heterogeneity: Tau <sup>2</sup> = 1.58; Chi <sup>2</sup> = 15.60, df = 3 (P = 0.001);   <sup>2</sup> = 81%								0.04 0.4 4 40 400
Test for overall effect: Z = 0.25 (P = 0.80)							l	0.01 0.1 1 10 100 High expression Low expression

Supplementary Figure S7: The correlation between H19 expression and distant metastasis (+ vs.-).



Supplementary Figure S8: The correlation between H19 expression and TNM stage (III-IV vs. I-II).